StocksIntellia Therapeutics IncNTLA

NTLA

Intellia Therapeutics Inc

67.63 2.17 (3.31%)
Prezzi ritardati da NASDAQ, in USD Mercato chiuso
Investi
S
67.62
B
67.83
Fissare il Post
Genome Engineering
Vertex, Verve team up to develop a gene editing drug for liver disease 🔹 $VRTX (Vertex Pharmaceuticals Incorporated) is broadening its reach in gene editing, announcing Wednesday a deal with $VERV (Verve Therapeutics Inc) to develop a one-time treatment for an undisclosed liver disease. Vertex will... Mostra di più Traduci
Feed Mercati
Top
MarketUpdates
Modificato